Literature DB >> 17101921

Infusion-related hypersensitivity reactions during natalizumab treatment.

J T Phillips1, P W O'Connor, E Havrdova, M Hutchinson, L Kappos, D H Miller, C H Polman, F D Lublin, G Giovannoni, A Wajgt, F Lynn, M A Panzara, A W Sandrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17101921     DOI： 10.1212/01.wnl.0000242629.66372.33

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis.

Authors:  J Theodore Phillips; Elliot M Frohman
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

2.  Innovative monoclonal antibody therapies in multiple sclerosis.

Authors:  Ralf A Linker; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

Review 3.  [Choice of early and escalation treatment options for multiple sclerosis].

Authors:  R A Linker; B C Kieseier
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

Review 4.  Multiple sclerosis.

Authors:  Richard Nicholas; Jeremy Chataway
Journal:  BMJ Clin Evid       Date:  2009-05-14

Review 5.  Multiple sclerosis.

Authors:  Richard Nicholas; Waqar Rashid
Journal:  BMJ Clin Evid       Date:  2012-02-10

Review 6.  Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Authors:  Per Soelberg Sorensen
Journal:  CNS Drugs       Date:  2022-05-19       Impact factor: 6.497

Review 7.  Natalizumab therapy for multiple sclerosis.

Authors:  Jeremy Chataway; David H Miller
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

8.  Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.

Authors:  Takahiko Saida; Kazumasa Yokoyama; Ryusuke Sato; Haruki Makioka; Yukihiko Iizuka; Masakazu Hase; Yan Ling; Shinichi Torii
Journal:  Neurol Ther       Date:  2017-11-08

9.  Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.

Authors:  Tobias Monschein; Sabine Salhofer-Polanyi; Patrick Altmann; Tobias Zrzavy; Assunta Dal-Bianco; Gabriel Bsteh; Paulus Rommer; Thomas Berger; Fritz Leutmezer
Journal:  J Neurol       Date:  2020-09-14       Impact factor: 4.849
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.